Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13834763 | 0.94 | IDO1 (0.55) | KDM4EPKMGPR119SYKBCDIN3D | |
| SCHEMBL5256392 | 0.85 | KDM4C (0.41) | KDM4EPKMGPR119SYKBCDIN3D | |
| SCHEMBL30703662 | 0.84 | KDM4E (0.61) | KDM4EPKMGPR119SYKBCDIN3D | |
| SCHEMBL22716661 | 0.84 | KDM4E (0.61) | KDM4EPKMGPR119SYKBCDIN3D | |
| SCHEMBL4718908 | 0.84 | KDM4E (0.48) | KDM4EPKMGPR119SYKBCDIN3D | |
| SCHEMBL2248074 | 0.84 | DYRK1A (0.56) | GPR119NAMPTCCNA2CDK2 | |
| SCHEMBL3871083 | 0.82 | GRIN2B (0.47) | CYP2D6CYP2C9GRIN2BCYP3A4 | |
| SCHEMBL6148442 | 0.82 | CYP2D6 (0.64) | KDM4EPKMGPR119CYP2D6CYP2C9 | |
| SCHEMBL5662290 | 0.82 | KDM4E (0.51) | KDM4EPKMGPR119SYKBCDIN3D | |
| SCHEMBL4665126 | 0.81 | GPR119 (0.52) | KDM4EPKMGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | J. Uriach Y Compañia S.A. (ES) | 2005-06-30 | — | — | US | disclosed |
| EP-1495044-A1 | HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY | J. Uriach y Compania S.A. (ES) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003084984-A1 | HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY | J. URIACH Y COMPANIA S.A. (ES) | 2003-10-16 | — | — | WO | disclosed |
| EP-0790998-B1 | AZO DERIVATIVES OF 5-AMINOSALICYLIC ACID FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | URIACH & CIA SA J (ES) | 2001-01-17 | — | — | EP | disclosed |
| EP-0738269-B1 | PIPERIDINE DERIVATIVES WITH PAF ANTAGONIST ACTIVITY | URIACH & CIA SA J (ES) | 2000-04-26 | — | — | EP | disclosed |
| EP-0790998-A1 | AZO DERIVATIVES OF 5-AMINOSALICYLIC ACID FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | J. URIACH & CIA. S.A. (ES) | 1997-08-27 | — | — | EP | disclosed |
| WO-1997009329-A1 | AZO DERIVATIVES OF 5-AMINOSALICYLIC ACID FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | J. URIACH & CIA. S.A. (ES) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | ITGB4, ITGA4, ITGA1 | KDM4E 470/4885PKM 3864/4885GPR119 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.